Contents
November 2018
Vol 3, Issue 29
Vol 3, Issue 29
Focus
- Developing combination immunotherapies against cancer that make sense
Mechanistic preclinical studies reveal that combination immunotherapies targeting PD-1 and GITR may demonstrate synergy in human cancer.
Research Articles
- Single-cell transcriptional analysis reveals ILC-like cells in zebrafish
Analyses of immune cells in rag1-deficient zebrafish led to the discovery of innate lymphoid cells in teleosts.
- Inhibitory killer cell immunoglobulin-like receptors strengthen CD8+ T cell–mediated control of HIV-1, HCV, and HTLV-1
Inhibitory killer cell immunoglobulin-like receptors (iKIRs) help maintain CD8+ T cell responses to human chronic viral infections.
- Combination cancer immunotherapy targeting PD-1 and GITR can rescue CD8+ T cell dysfunction and maintain memory phenotype
Synergistic CD8+ T cell activation by antibodies to PD-1 and GITR in cancer immunotherapy depends on the CD226 costimulatory pathway.
- Clonal expansion and compartmentalized maintenance of rhesus macaque NK cell subsets
Macaque barcoding reveals NK oligoclonal expansion and persistence independent of production from HSPCs or immature NK cells.
Editors' Choice
- Trypping up antigenic variation in sleeping sickness
Histone variants ensure proper genome partitioning in trypanosomes to restrict antigenic variation.
- A sweet alternative: maintaining M2 macrophage polarization
Glycolytic metabolism functions as a backup mechanism for M2 macrophage polarization when oxidative phosphorylation is disrupted.
About The Cover
ONLINE COVER Double Feature. This month's cover illustration is an artist's depiction of changes in intratumoral CD8+ T cell function elicited by combination cancer immunotherapy. Wang et al. report that treatment with both agonist anti-GITR and blocking anti-PD-1 antibodies (only affecting the right half of the T cell) triggers transcriptional pathways that lead to enhanced cellular activation (orange cell membrane) and increased cytokine production (dark blue ovals emerging from cell surface). Synergistic activation of the in vivo CD8+ T cell response is associated with robust tumor elimination (with tan cancer cells infiltrating only alongside the untreated left half of the T cell). [CREDIT: RACHEL URKOWITZ]